Welcome to our dedicated page for Tango Therapeutics SEC filings (Ticker: TNGX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Tango Therapeutics, Inc. filings document a clinical-stage precision oncology business and its Nasdaq-listed common stock. Current reports disclose operating and financial results, business highlights for vopimetostat and related development programs, material agreements, capital-raising arrangements such as at-the-market common stock sales, and updates to governance and executive leadership.
Proxy and compensation disclosures cover board matters, executive pay, pay-versus-performance data, equity awards, and shareholder voting matters. The company’s filings also address officer appointments and departures, separation and employment agreements, compensatory arrangements, capital structure, risk factors, and other material events affecting its biotechnology operations.
Tango Therapeutics reported a larger net loss as it shifts from collaboration funding to equity capital while advancing its oncology pipeline. For the quarter ended June 30, 2026, net loss was $55.3 million versus $38.9 million a year earlier, with no collaboration revenue following the 2025 truncation of its Gilead research agreement.
Research and development expense rose to $37.2 million, driven by vopimetostat and TNG456 trials, while general and administrative expense nearly doubled to $22.6 million, largely from higher stock-based compensation. A June 2026 equity offering and at-the-market sales lifted cash, cash equivalents and marketable securities to about $1.0 billion, which the company expects will fund operations for at least 12 months.
Clinically, vopimetostat combinations showed encouraging early data in MTAP-deleted, RAS-mutant cancers, including high objective response and disease control rates in pancreatic and lung cohorts, and the company plans a Phase 3 trial in frontline pancreatic cancer. Tango is deprioritizing TNG260, TNG961 and has stopped new enrollment in TNG908 to focus resources on its PRMT5 franchise.
Tango Therapeutics amended an earlier disclosure to add the terms of a Separation Agreement with former Executive Chair Dr. Barbara Weber, whose employment and board roles ended effective August 3, 2026. The agreement was executed on August 6, 2026.
Dr. Weber is entitled to base-salary severance through December 31, 2026, paid in installments, and reimbursement of monthly COBRA premiums through the same date, conditional on not revoking the agreement. Equity terms include full acceleration of outstanding options and RSUs (subject to Compensation Committee approval) and extension of the post-termination exercise period for vested and accelerated options to the earlier of August 3, 2027 or each option’s original expiration. She will also receive a pro‑rata 2026 annual incentive, if earned based on company and individual performance, paid with other employees’ bonuses no later than March 15, 2027.
Tango Therapeutics, Inc. reports that Dr. Barbara Weber’s employment as Executive Chair ended on August 3, 2026, in accordance with her Amended and Restated Employment Agreement dated January 8, 2026, and that she is deemed to have resigned from all officer and board positions.
The company states that her resignation was not due to any disagreement regarding operations, practices or policies. Subject to Dr. Weber executing and not revoking a Separation Agreement, she is offered base-salary severance and COBRA reimbursement through December 31, 2026, acceleration of equity awards equal to 12 additional months of vesting, an extended stock option exercise period to the earlier of August 3, 2027 or the options’ original expirations, and a pro‑rated 2026 annual incentive payable no later than March 15, 2027. The company plans to file the Separation Agreement once it is fully effective and includes cautionary language regarding forward‑looking statements.
Tango Therapeutics, Inc. reported that Crystal Adam, President, R&D, exercised stock options to acquire 27,000 shares of common stock at $5.20 per share and, on the same date, sold 27,000 shares in two tranches of 5,267 and 21,733 shares at weighted average prices of $26.7895 and $27.3509 per share. These transactions were effected under a Rule 10b5-1 trading plan adopted on October 27, 2025, and following the option exercise she held 287,040 stock options to purchase common shares.
TNG Therapeutics Inc. insider Adam Crystal filed a notice to sell 81,000 shares of common stock through Morgan Stanley Smith Barney LLC, with an aggregate value of $2,201,580.00, on August 3, 2026 following an exercise of stock options. The filing also lists prior Rule 10b5-1 sales totaling 54,000 shares between June and July 2026.
Tango Therapeutics, Inc. President, R&D Crystal Adam reported an exercise-and-sell transaction in company common stock. She exercised stock options for 27,000 shares at $5.20 per share, then sold a total of 27,000 shares in open-market trades at weighted-average prices around $29–$30.
The filing shows two sale blocks: 7,371 shares at a weighted-average price of $30.2464 and 19,629 shares at $29.3424. After these transactions, Adam directly holds 115,743 shares of common stock. The sales were made under a pre-arranged Rule 10b5-1 trading plan adopted on October 27, 2025, indicating they were scheduled in advance.
Tango Therapeutics director Robert Azelby reported equity awards from the company. He received 5,740 shares of Common Stock in the form of restricted stock units (RSUs), with each RSU representing one future share.
The RSUs will vest in three substantially equal annual installments following the grant date, as long as he remains in continuous service. He was also granted a stock option covering 35,910 shares of Common Stock at an exercise price of $27.97 per share. This option vests in 36 substantially equal monthly installments over three years, subject to continued service, and expires on June 19, 2036. These are compensation-related grants, not open‑market purchases.
Tango Therapeutics, Inc. director Robert Azelby has filed a Form 3, which is an initial statement of beneficial ownership as a company insider. The filing lists him as a director but does not report any stock transactions or current holdings in this excerpt.
Tango Therapeutics, Inc. expanded its Board of Directors to seven members and appointed biopharmaceutical executive Robert Azelby as a Class II director, with a term running until the 2029 annual meeting of stockholders. The Board determined he is independent under Nasdaq listing standards and named him to the Compensation Committee and the Nominating and Corporate Governance Committee, effective June 23, 2026.
Under the non-employee director compensation program, he will receive a stock option for 35,910 shares at an exercise price of $27.97 per share, vesting monthly over three years, and an RSU award for 5,740 shares vesting annually over three years, along with cash retainers for Board and committee service. The accompanying press release highlights his three decades of oncology and commercial leadership and notes his appointment comes as Tango advances its investigational PRMT5 inhibitor vopimetostat toward potential late-stage development for MTAP-deleted cancers, including pancreatic cancer.
TNGX affiliate filed a Form 144 reporting proposed sales of Common Stock. The notice lists three transactions by NEXTECH CROSSOVER I SCSP: 06/11/2026 500,000 shares for $15,018,000; 06/12/2026 500,000 shares for $14,870,050; and 06/15/2026 2,500,000 shares for $75,164,250.
The filing identifies these as Common Stock sales tied to prior private placements and lists broker-dealer information. The notice is procedural under Form 144 and reports the affiliate's intended dispositions on the stated dates.